Symbols / EYPT
EYPT Chart
About
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.41B |
| Enterprise Value | 1.23B | Income | -205.75M | Sales | 42.34M |
| Book/sh | 2.88 | Cash/sh | 2.46 | Dividend Yield | — |
| Payout | 0.00% | Employees | 165 | IPO | — |
| P/E | — | Forward P/E | -5.85 | PEG | — |
| P/S | 33.34 | P/B | 5.93 | P/C | — |
| EV/EBITDA | -5.69 | EV/Sales | 29.07 | Quick Ratio | 6.81 |
| Current Ratio | 7.18 | Debt/Eq | 11.62 | LT Debt/Eq | — |
| EPS (ttm) | -3.00 | EPS next Y | -2.91 | EPS Growth | — |
| Revenue Growth | -90.80% | Earnings | 2026-03-04 | ROA | -49.38% |
| ROE | -98.23% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -64.21% | Profit Margin | 0.00% | Shs Outstand | 82.79M |
| Shs Float | 61.19M | Short Float | 12.10% | Short Ratio | 9.44 |
| Short Interest | — | 52W High | 19.11 | 52W Low | 3.91 |
| Beta | 1.79 | Avg Volume | 1.26M | Volume | 1.14M |
| Target Price | $36.33 | Recom | Strong_buy | Prev Close | $17.07 |
| Price | $17.05 | Change | -0.12% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$36.33
Mean price target
2. Current target
$17.64
Latest analyst target
3. DCF / Fair value
$-27.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$17.64
Low
$20.00
High
$68.00
Mean
$36.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-06 | main | RBC Capital | Outperform → Outperform | $39 |
| 2025-08-07 | main | Chardan Capital | Buy → Buy | $27 |
| 2025-08-06 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-06-17 | init | RBC Capital | — → Outperform | $28 |
| 2025-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-05-16 | main | Mizuho | Outperform → Outperform | $26 |
| 2025-05-08 | main | Chardan Capital | Buy → Buy | $27 |
| 2025-03-06 | main | Chardan Capital | Buy → Buy | $33 |
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-02-06 | main | Chardan Capital | Buy → Buy | $33 |
| 2025-01-07 | init | Citigroup | — → Buy | $33 |
| 2024-12-05 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-11-11 | main | Baird | Outperform → Outperform | $33 |
| 2024-11-11 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-11-08 | main | Chardan Capital | Buy → Buy | $33 |
| 2024-10-29 | main | Chardan Capital | Buy → Buy | $28 |
| 2024-10-25 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-08-13 | main | JP Morgan | Overweight → Overweight | $29 |
| 2024-06-28 | main | Chardan Capital | Buy → Buy | $28 |
| 2024-06-27 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
- $EYPT stock is up 8% today. Here's what we see in our data. - Quiver Quantitative Mon, 23 Feb 2026 19
- EyePoint lines up March investor talks at TD Cowen, Barclays, Jefferies, RBC - Stock Titan ue, 24 Feb 2026 12
- EyePoint (EYPT) Valuation Check As New Chief Commercial Officer Joins Ahead Of Potential DURAVYU Launch - simplywall.st ue, 24 Feb 2026 00
- EyePoint Announces Participation at Upcoming Investor Conferences - GlobeNewswire ue, 24 Feb 2026 12
- How (EYPT) Movements Inform Risk Allocation Models - Stock Traders Daily ue, 24 Feb 2026 15
- EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? - Yahoo Finance Wed, 18 Feb 2026 12
- EyePoint Pharmaceuticals, Inc. (EYPT) Stock Analysis: Exploring 112% Potential Upside with Innovative Retinal Treatments - DirectorsTalk Interviews Fri, 05 Dec 2025 08
- A Look At EyePoint Pharmaceuticals (EYPT) Valuation As Models Suggest A Large Gap To Fair Value - Yahoo Finance hu, 19 Feb 2026 15
- Lucentis launch veteran tapped to steer EyePoint’s next eye drug - Stock Titan Wed, 18 Feb 2026 12
- EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors - simplywall.st Wed, 04 Feb 2026 08
- $EYPT stock is up 14% today. Here's what we see in our data. - Quiver Quantitative hu, 04 Dec 2025 08
- Despite currently being unprofitable, EyePoint (NASDAQ:EYPT) has delivered a 195% return to shareholders over 3 years - Yahoo Finance Mon, 02 Feb 2026 08
- 13,500-Share Grant: EyePoint Issues Stock Options at $11.73 Exercise Price, Vesting 4 Years - Stock Titan hu, 16 Oct 2025 07
- $EYPT stock is up 11% today. Here's what we see in our data. - Quiver Quantitative Mon, 17 Nov 2025 08
- EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance Wed, 05 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2437 | 36555.0 | — | Sale at price 15.00 per share. | RIBEIRO RAMIRO | Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 2437 | 20130.0 | — | Conversion of Exercise of derivative security at price 8.26 per share. | RIBEIRO RAMIRO | Officer | — | 2026-02-17 00:00:00 | D |
| 2 | 15285 | nan | — | — | ELSTON GEORGE O | Chief Financial Officer | — | 2026-01-06 00:00:00 | D |
| 3 | 75133 | nan | — | — | LURKER NANCY S | Director | — | 2026-01-06 00:00:00 | D |
| 4 | 20793 | nan | — | — | DUKER JAY S | Chief Executive Officer | — | 2026-01-06 00:00:00 | D |
| 5 | 34667 | nan | — | — | ELSTON GEORGE O | Chief Financial Officer | — | 2026-01-05 00:00:00 | D |
| 6 | 12666 | nan | — | — | LURKER NANCY S | Director | — | 2026-01-05 00:00:00 | D |
| 7 | 95000 | nan | — | — | DUKER JAY S | Chief Executive Officer | — | 2026-01-05 00:00:00 | D |
| 8 | 42544 | 727319.0 | — | Sale at price 17.10 per share. | RIBEIRO RAMIRO | Officer | — | 2026-01-05 00:00:00 | D |
| 9 | 29250 | 241605.0 | — | Conversion of Exercise of derivative security at price 8.26 per share. | RIBEIRO RAMIRO | Officer | — | 2026-01-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -282.87K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -129.23M | -67.65M | -74.36M | -52.21M |
| TotalUnusualItems | 0.00 | -1.35M | -22.26M | 2.06M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -1.35M | -22.26M | 2.06M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -130.87M | -70.80M | -102.25M | -58.42M |
| ReconciledDepreciation | 1.54M | 464.00K | 2.45M | 2.77M |
| ReconciledCostOfRevenue | 3.71M | 4.63M | 7.93M | 7.87M |
| EBITDA | -129.23M | -69.00M | -96.62M | -50.15M |
| EBIT | -130.77M | -69.47M | -99.06M | -52.92M |
| NetInterestIncome | 15.07M | 5.70M | -1.06M | -5.21M |
| InterestExpense | 14.00K | 1.25M | 3.19M | 5.50M |
| InterestIncome | 15.09M | 6.95M | 2.13M | 292.00K |
| NormalizedIncome | -130.87M | -69.73M | -80.00M | -60.48M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -130.87M | -70.80M | -102.25M | -58.42M |
| TotalExpenses | 189.13M | 121.08M | 120.34M | 92.22M |
| TotalOperatingIncomeAsReported | -145.85M | -75.07M | -99.64M | -55.28M |
| DilutedAverageShares | 56.30M | 38.90M | 37.32M | 28.76M |
| BasicAverageShares | 56.30M | 38.90M | 37.32M | 28.76M |
| DilutedEPS | -2.32 | -1.82 | -2.74 | -2.03 |
| BasicEPS | -2.32 | -1.82 | -2.74 | -2.03 |
| DilutedNIAvailtoComStockholders | -130.87M | -70.80M | -102.25M | -58.42M |
| NetIncomeCommonStockholders | -130.87M | -70.80M | -102.25M | -58.42M |
| NetIncome | -130.87M | -70.80M | -102.25M | -58.42M |
| NetIncomeIncludingNoncontrollingInterests | -130.87M | -70.80M | -102.25M | -58.42M |
| NetIncomeContinuousOperations | -130.87M | -70.80M | -102.25M | -58.42M |
| TaxProvision | 90.00K | 83.00K | 0.00 | |
| PretaxIncome | -130.78M | -70.71M | -102.25M | -58.42M |
| OtherIncomeExpense | -1.35M | -22.26M | 2.06M | |
| SpecialIncomeCharges | 0.00 | -1.35M | -22.26M | 2.06M |
| OtherSpecialCharges | 1.35M | 1.56M | -2.06M | |
| ImpairmentOfCapitalAssets | 0.00 | 20.70M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 15.07M | 5.70M | -1.06M | -5.21M |
| InterestExpenseNonOperating | 14.00K | 1.25M | 3.19M | 5.50M |
| InterestIncomeNonOperating | 15.09M | 6.95M | 2.13M | 292.00K |
| OperatingIncome | -145.85M | -75.07M | -78.94M | -55.28M |
| OperatingExpense | 185.41M | 116.45M | 112.02M | 84.04M |
| DepreciationAmortizationDepletionIncomeStatement | 0.00 | 2.05M | 2.46M | |
| DepreciationAndAmortizationInIncomeStatement | 0.00 | 2.05M | 2.46M | |
| Amortization | 0.00 | 2.05M | 2.46M | |
| AmortizationOfIntangiblesIncomeStatement | 0.00 | 2.05M | 2.46M | |
| ResearchAndDevelopment | 132.93M | 64.66M | 49.64M | 28.50M |
| SellingGeneralAndAdministration | 52.49M | 51.79M | 60.32M | 53.08M |
| SellingAndMarketingExpense | 131.00K | 11.69M | 25.51M | 27.50M |
| GeneralAndAdministrativeExpense | 52.36M | 40.10M | 34.82M | 25.57M |
| OtherGandA | 52.36M | 40.10M | 34.82M | 25.57M |
| GrossProfit | 39.56M | 41.39M | 33.08M | 28.76M |
| CostOfRevenue | 3.71M | 4.63M | 8.33M | 8.18M |
| TotalRevenue | 43.27M | 46.02M | 41.40M | 36.94M |
| OperatingRevenue | 43.27M | 46.02M | 41.40M | 36.94M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 68.27M | 49.04M | 34.08M | 33.91M |
| ShareIssued | 68.27M | 49.04M | 34.08M | 33.91M |
| TotalDebt | 21.86M | 4.91M | 45.77M | 39.20M |
| TangibleBookValue | 336.50M | 266.32M | 96.37M | 161.63M |
| InvestedCapital | 336.50M | 266.32M | 136.15M | 220.94M |
| WorkingCapital | 334.26M | 281.54M | 138.27M | 214.09M |
| NetTangibleAssets | 336.50M | 266.32M | 96.37M | 161.63M |
| CapitalLeaseObligations | 21.86M | 4.91M | 5.98M | 2.64M |
| CommonStockEquity | 336.50M | 266.32M | 96.37M | 184.38M |
| TotalCapitalization | 336.50M | 266.32M | 125.68M | 220.94M |
| TotalEquityGrossMinorityInterest | 336.50M | 266.32M | 96.37M | 184.38M |
| StockholdersEquity | 336.50M | 266.32M | 96.37M | 184.38M |
| GainsLossesNotAffectingRetainedEarnings | 1.03M | 864.00K | 786.00K | 841.00K |
| OtherEquityAdjustments | 1.03M | 864.00K | 786.00K | 841.00K |
| RetainedEarnings | -873.02M | -742.15M | -671.35M | -569.10M |
| AdditionalPaidInCapital | 1.21B | 1.01B | 766.90M | 752.60M |
| CapitalStock | 68.00K | 49.00K | 34.00K | 34.00K |
| CommonStock | 68.00K | 49.00K | 34.00K | 34.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 81.96M | 88.86M | 83.99M | 78.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 32.92M | 25.60M | 49.45M | 55.33M |
| OtherNonCurrentLiabilities | 205.00K | 600.00K | 2.35M | |
| NonCurrentDeferredLiabilities | 10.85M | 20.69M | 13.56M | 14.56M |
| NonCurrentDeferredRevenue | 10.85M | 20.69M | 13.56M | 14.56M |
| LongTermDebtAndCapitalLeaseObligation | 21.86M | 4.91M | 35.29M | 38.42M |
| LongTermCapitalLeaseObligation | 21.86M | 4.91M | 5.98M | 1.86M |
| LongTermDebt | 29.31M | 36.56M | ||
| CurrentLiabilities | 49.05M | 63.26M | 34.54M | 23.66M |
| OtherCurrentLiabilities | 1.44M | 646.00K | 579.00K | |
| CurrentDeferredLiabilities | 17.78M | 38.59M | 1.21M | 1.07M |
| CurrentDeferredRevenue | 17.78M | 38.59M | 1.21M | 1.07M |
| CurrentDebtAndCapitalLeaseObligation | 10.47M | 782.00K | ||
| CurrentCapitalLeaseObligation | 579.00K | 782.00K | ||
| CurrentDebt | 10.47M | |||
| LineOfCredit | 0.00 | 10.47M | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.83M | 12.63M | 9.52M | 7.32M |
| PayablesAndAccruedExpenses | 17.99M | 11.39M | 12.76M | 14.49M |
| CurrentAccruedExpenses | 6.27M | 4.89M | 6.84M | 7.10M |
| Payables | 11.72M | 6.50M | 5.92M | 7.38M |
| AccountsPayable | 11.72M | 6.50M | 5.92M | 7.38M |
| TotalAssets | 418.46M | 355.18M | 180.36M | 263.37M |
| TotalNonCurrentAssets | 35.16M | 10.38M | 7.55M | 25.63M |
| OtherNonCurrentAssets | 5.98M | 150.00K | 150.00K | 150.00K |
| GoodwillAndOtherIntangibleAssets | 0.00 | 22.75M | ||
| OtherIntangibleAssets | 22.75M | |||
| NetPPE | 29.18M | 10.23M | 7.40M | 2.73M |
| AccumulatedDepreciation | -4.06M | -2.57M | -2.11M | -1.26M |
| GrossPPE | 33.23M | 12.80M | 9.51M | 3.98M |
| Leases | 4.13M | 1.01M | 1.01M | 255.00K |
| ConstructionInProgress | 1.51M | 3.73M | 0.00 | |
| OtherProperties | 27.60M | 8.07M | 8.50M | 3.73M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 383.31M | 344.80M | 172.81M | 237.75M |
| OtherCurrentAssets | 1.41M | 1.01M | 782.00K | 4.22M |
| PrepaidAssets | 8.08M | 8.03M | 9.08M | 3.70M |
| Inventory | 2.31M | 3.91M | 2.89M | 3.62M |
| FinishedGoods | 0.00 | 1.72M | 398.00K | 484.00K |
| WorkInProcess | 648.00K | 882.00K | 1.08M | 405.00K |
| RawMaterials | 1.66M | 1.30M | 1.41M | 2.73M |
| Receivables | 607.00K | 805.00K | 15.50M | 18.35M |
| AccountsReceivable | 607.00K | 805.00K | 15.50M | 18.35M |
| CashCashEquivalentsAndShortTermInvestments | 370.91M | 331.05M | 144.56M | 211.56M |
| OtherShortTermInvestments | 271.21M | 49.79M | 48.93M | 32.97M |
| CashAndCashEquivalents | 99.70M | 281.26M | 95.63M | 178.59M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -130.28M | -1.61M | -67.16M | -50.25M |
| RepaymentOfDebt | -105.00K | -45.81M | -71.77M | -146.00K |
| IssuanceOfDebt | 0.00 | 5.30M | 73.88M | 0.00 |
| IssuanceOfCapitalStock | 163.31M | 226.17M | 0.00 | 216.82M |
| CapitalExpenditure | -4.05M | -3.48M | -2.15M | -156.00K |
| InterestPaidSupplementalData | 0.00 | 1.41M | 2.60M | 4.85M |
| IncomeTaxPaidSupplementalData | 600.00K | 0.00 | ||
| EndCashPosition | 99.85M | 281.41M | 95.78M | 178.74M |
| BeginningCashPosition | 281.41M | 95.78M | 178.74M | 45.06M |
| EffectOfExchangeRateChanges | 0.00 | |||
| ChangesInCash | -181.56M | 185.63M | -82.96M | 133.68M |
| FinancingCashFlow | 164.02M | 187.07M | -690.00K | 216.90M |
| CashFlowFromContinuingFinancingActivities | 164.02M | 187.07M | -690.00K | 216.90M |
| NetOtherFinancingCharges | -5.18M | -1.97M | -3.19M | -150.00K |
| ProceedsFromStockOptionExercised | 6.00M | 3.38M | 395.00K | 373.00K |
| NetCommonStockIssuance | 163.31M | 226.17M | 0.00 | 216.82M |
| CommonStockIssuance | 163.31M | 226.17M | 0.00 | 216.82M |
| NetIssuancePaymentsOfDebt | -105.00K | -40.51M | 2.10M | -146.00K |
| NetShortTermDebtIssuance | -10.47M | 10.47M | 0.00 | |
| ShortTermDebtPayments | -15.78M | -33.40M | 0.00 | |
| ShortTermDebtIssuance | 5.30M | 43.88M | 0.00 | |
| NetLongTermDebtIssuance | -105.00K | -40.51M | 2.10M | -146.00K |
| LongTermDebtPayments | -105.00K | -45.81M | -71.77M | -146.00K |
| LongTermDebtIssuance | 0.00 | 5.30M | 73.88M | 0.00 |
| InvestingCashFlow | -219.35M | -3.31M | -17.27M | -33.12M |
| CashFlowFromContinuingInvestingActivities | -219.35M | -3.31M | -17.27M | -33.12M |
| NetInvestmentPurchaseAndSale | -215.30M | 168.00K | -15.12M | -32.97M |
| SaleOfInvestment | 183.00M | 55.28M | 124.00M | 0.00 |
| PurchaseOfInvestment | -398.30M | -55.12M | -139.12M | -32.97M |
| NetPPEPurchaseAndSale | -4.05M | -3.48M | -2.15M | -156.00K |
| PurchaseOfPPE | -4.05M | -3.48M | -2.15M | -156.00K |
| OperatingCashFlow | -126.23M | 1.88M | -65.00M | -50.10M |
| CashFlowFromContinuingOperatingActivities | -126.23M | 1.88M | -65.00M | -50.10M |
| ChangeInWorkingCapital | -27.77M | 58.88M | -3.02M | -1.74M |
| ChangeInOtherWorkingCapital | -29.03M | 44.48M | -799.00K | -959.00K |
| ChangeInOtherCurrentAssets | -5.83M | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | 5.73M | 1.52M | 1.20M | 8.48M |
| ChangeInInventory | 1.60M | -1.55M | -760.00K | 1.35M |
| ChangeInReceivables | -244.00K | 14.43M | -2.66M | -10.60M |
| ChangesInAccountReceivables | -244.00K | 14.43M | -2.66M | -10.60M |
| OtherNonCashItems | -5.95M | -856.00K | -558.00K | 628.00K |
| StockBasedCompensation | 36.74M | 12.06M | 14.18M | 7.45M |
| ProvisionandWriteOffofAssets | 0.00 | 693.00K | 1.95M | 1.28M |
| AssetImpairmentCharge | 0.00 | 20.70M | 0.00 | |
| DeferredTax | 90.00K | 83.00K | 0.00 | |
| DeferredIncomeTax | 90.00K | 83.00K | 0.00 | |
| DepreciationAmortizationDepletion | 1.54M | 464.00K | 2.45M | 2.77M |
| DepreciationAndAmortization | 1.54M | 464.00K | 2.45M | 2.77M |
| AmortizationCashFlow | 0.00 | 2.05M | 2.46M | |
| AmortizationOfIntangibles | 0.00 | 2.05M | 2.46M | |
| Depreciation | 1.54M | 464.00K | 396.00K | 311.00K |
| OperatingGainsLosses | 1.35M | 1.56M | -2.06M | |
| NetIncomeFromContinuingOperations | -130.87M | -70.80M | -102.25M | -58.42M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for EYPT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|